Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.36 |
| ▸ | CTSD | P07339 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18097298 | 1.00 | BACE1 (0.38) | BACE1BACE2CTSDCNR2ACHE | |
| SCHEMBL18097515 | 0.82 | BACE1 (0.36) | BACE1BACE2CTSDCNR2 | |
| SCHEMBL17394883 | 0.78 | MAPT (0.37) | BACE1 | |
| SCHEMBL17394884 | 0.78 | MAPT (0.37) | BACE1 | |
| SCHEMBL1975057 | 0.76 | SIRT6 (0.41) | BACE1BACE2CTSDCNR2GABRA1 | |
| SCHEMBL28408353 | 0.75 | KDM1A (0.37) | ACACB | |
| SCHEMBL17395042 | 0.74 | BACE1 (0.38) | BACE1ACACB | |
| SCHEMBL16833475 | 0.74 | BACE1 (0.36) | BACE1BACE2 | |
| SCHEMBL16463484 | 0.74 | POLB (0.41) | BACE1BACE2CTSDCNR2GABRA1 | |
| SCHEMBL16833478 | 0.74 | BACE1 (0.36) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034687-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200308166-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3271355-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-10723729-B2 | BACE1 inhibitors | Hoffmann-Le Roche Inc. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190337936-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-11-07 | — | — | US | disclosed |
| US-10399969-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180319787-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180057485-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | US | disclosed |
| EP-3271355-A1 | BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016150785-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337936-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
| US-10399969-B2 | BACE1 inhibitors | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
| US-20180319787-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
| US-20200308166-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
| US-10723729-B2 | BACE1 inhibitors | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
| US-20180057485-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
| US-11034687-B2 | BACE1 inhibitors | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.